Sanofi re­cruits No­var­tis' top phar­ma ex­ec Paul Hud­son as its new CEO — so what hap­pens now?

Sanofi’s board has turned to some­one who’s not French to be its next CEO.

The Paris-based phar­ma gi­ant named No­var­tis phar­ma chief Paul Hud­son — a British phar­ma ex­ec­u­tive with an in­ter­na­tion­al pedi­gree — to the top post as cur­rent CEO Olivi­er Brandi­court heads off to an ear­ly “re­tire­ment.”

Marie-France Tschudin AAA

In a care­ful­ly or­ches­trat­ed re­sponse, No­var­tis CEO Vas Narasimhan con­grat­u­lat­ed Hud­son and named Marie-France Tschudin, a Swiss cit­i­zen who’s head­ing up the re­cent­ly ac­quired can­cer group Ad­vanced Ac­cel­er­a­tor Ap­pli­ca­tions, as Hud­son’s re­place­ment. In do­ing so, he im­me­di­ate­ly po­si­tioned Tschudin — who speaks 6 lan­guages — as a top can­di­date for any fu­ture Big Phar­ma CEO open­ing.

Hud­son joined No­var­tis and the ex­ec­u­tive com­mit­tee just three years ago, af­ter serv­ing as the US phar­ma chief for As­traZeneca. He has a de­gree in eco­nom­ics from Man­ches­ter Met­ro­pol­i­tan Uni­ver­si­ty in the UK.

Hud­son will take the top slot on Sep­tem­ber 1, where he’ll be greet­ed by an ex­tra­or­di­nary chal­lenge. The com­pa­ny has an R&D group with a rep for slow mo­tion move­ment and a mar­ket­ing team that’s faced with some tough chal­lenges on the di­a­betes front, among oth­ers.

In­vestors re­spond­ed warm­ly to the ac­tion, bid­ding Sanofi’s shares up 5.5%  on Fri­day.

Brandi­court came on board just 4 years ago, fol­low­ing in the wake of Chris Viehbach­er, who was axed by the Gal­lic board and pow­er­ful chair­man — Serge Wein­berg — in charge of Sanofi af­ter mov­ing back home to the US. The French clear­ly want­ed a na­tive to run the com­pa­ny at the time, but ap­par­ent­ly feel that pro­fes­sion­al­ism trumps na­tion­al­i­ty as it works to­ward a turn­around.

One of Reuters sources, who tipped the wire ser­vices off ear­ly on the an­nounce­ment, said that Hud­son was picked be­cause of his sol­id man­age­ment ex­pe­ri­ence and ex­pe­ri­ence with dig­i­tal tech­nolo­gies, where No­var­tis has been care­ful­ly fo­cused.

So now the guess­ing games be­gin. What will Hud­son do to shake things up at Sanofi, where its R&D or­ga­ni­za­tion has pro­duced lit­tle of re­al val­ue, with the pos­si­ble ex­cep­tion of their late-stage can­cer drug isat­ux­imab?

Sanofi ex­e­cut­ed ma­jor al­liances with Re­gen­eron and Al­ny­lam on ground­break­ing drugs, but on its own the com­pa­ny is known as large­ly mori­bund and bu­reau­crat­ic, tak­ing a long stretch to fi­nal­ly ex­e­cute on the M&A front un­der Brandi­court. And now they’ve backed away from those al­liances to lean more heav­i­ly on the pipeline and R&D chief John Reed.

If Hud­son’s back­ground at No­var­tis is an in­di­ca­tor, he may turn to deal­mak­ing to help en­liv­en the late-stage pipeline, where all big phar­mas are judged. An in­ter­nal shake­up in key ar­eas like on­col­o­gy may al­so be in the off­ing, as new ex­ecs like Di­et­mar Berg­er join up. And just about every new CEO — Dave Ricks and Em­ma Walm­s­ley, for ex­am­ple — like to bring out the axe to chop away at the dead wood be­fore adding any­thing.

Reed has al­ready re­vamped the pipeline. But look for an even greater re­liance on the US re­search ops around Boston to car­ry the bulk of the weight.

Any­one look­ing for the next sig­nal on Hud­son’s sta­tus should look to his com­pen­sa­tion pack­age. Brandi­court took home a 2018 com­pen­sa­tion pack­age of $8.1 mil­lion — down $2.7 mil­lion, a painful 33% drop — com­pared to his al­lot­ment for 2017. Eu­ro­pean ex­ecs tend to be paid sig­nif­i­cant­ly less than their US coun­ter­parts, but a cut in com­pen­sa­tion like that un­der­scored the board’s feel­ings about Brandi­court’s lack of ef­fec­tive­ness as a man­ag­er.

How much did Hud­son get in his ne­go­ti­a­tions?

Im­age: Paul Hud­son (No­var­tis)

 

The DCT-OS: A Tech­nol­o­gy-first Op­er­at­ing Sys­tem - En­abling Clin­i­cal Tri­als

As technology-enabled clinical research becomes the new normal, an integrated decentralized clinical trial operating system can ensure quality, deliver consistency and improve the patient experience.

The increasing availability of COVID-19 vaccines has many of us looking forward to a time when everyday things return to a state of normal. Schools and teachers are returning to classrooms, offices and small businesses are reopening, and there’s a palpable sense of optimism that the often-awkward adjustments we’ve all made personally and professionally in the last year are behind us, never to return. In the world of clinical research, however, some pandemic-necessitated adjustments are proving to be more than emergency stopgap measures to ensure trial continuity — and numerous decentralized clinical trial (DCT) tools and methodologies employed within the last year are likely here to stay as part of biopharma’s new normal.

'Chang­ing the whole game of drug dis­cov­ery': Leg­endary R&D vet Roger Perl­mut­ter leaps back in­to work as a biotech CEO

Roger Perlmutter needs no introduction to anyone remotely involved in biopharma. As the R&D chief first at Amgen and then Merck, he’s built a stellar reputation and a prolific career steering new drugs toward the market for everything from cancer to infectious diseases.

But for years, he’s also held a less known title: science partner at The Column Group, where he’s regularly consulted about the various ideas the VCs had for new startups.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Onno van de Stolpe, Galapagos CEO (Thierry Roge/Belga Mag/AFP via Getty Images)

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months after Gilead gutted its rich partnership with Galapagos following a bitter setback at the FDA, the Belgian biotech is hunkering down and chopping the pipeline in an effort to conserve cash while their BD team pursues a mission to find a “transformative” deal for the company.

The filgotinib disaster didn’t warrant a mention as Galapagos laid out its Darwinian restructuring plans. Forced to make choices, the company is ditching its IPF molecule ’1205, while moving ahead with a Phase II IPF study for its chitinase inhibitor ’4617.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, Getty

Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Moderna is definitively more concerned with keeping pace with Pfizer in the race to vaccinate the world against Covid-19 than it is with Wednesday’s decision from the Biden administration to back an intellectual property waiver that aims to increase vaccine supplies worldwide.

In its first quarter earnings call on Thursday, Moderna CEO Stéphane Bancel shrugged off any suggestion that the newly US-backed intellectual property waiver would impact his company’s vaccine or bottom line. Still, the company’s stock price fell by about 9% in early morning trading.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Nick Leschly at Endpoints' JPM20 Breakfast Panel (Jeff Rumans for Endpoints News)

2sev­en­ty: Nick Leschly brings a trio of top ex­ecs with him on top-speed flight from the blue­bird nest

After serving more than a decade as bluebird bio’s chief bluebird, Nick Leschly is switching it up.

At some point this year, Leschly will officially become the CEO of 2seventy — the new company that will house bluebird’s oncology business while Andrew Obenshain, the current president for severe genetic diseases, will take over as CEO to oversee the rare disease pipeline remaining at bluebird.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Cynthia Butitta (L) and Joe Jimenez

Is that an­oth­er IPO in the mak­ing? Ex-No­var­tis CEO Joe Jimenez and a lead Kite play­er take up new posts at an off-the-shelf ri­val to 2 pi­o­neer­ing drugs

Right on the heels of taking on a $160 million crossover round in a likely leap to Nasdaq, Century Therapeutics CEO Lalo Flores is now pushing ahead with the high-profile ex-Novartis chief Joe Jimenez as chairman.

Jimenez’s greatest fame at Novartis was earned for one of its weakest products, as their pioneering personalized CAR-T Kymriah won the honors for the first such drug to make it to the market. Now a host of players, including Century, are barreling in behind the frontrunners with allogeneic rivals that can be created for off-the-shelf use.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Ad­comm splits slight­ly in fa­vor of FDA ap­prov­ing Chemo­Cen­tryx’s rare dis­ease drug

The FDA’s Arthritis Advisory Committee on Thursday voted 10 for and 8 against the approval of ChemoCentryx’s $CCXI investigational drug avacopan as a treatment for adults with a rare and serious disease known as anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis.

The vote on whether the FDA should approve the drug was preceded by a split vote of 9 to 9 on whether the efficacy data support approval, and 10 to 8 that the safety profile of avacopan is adequate enough to support approval.

Aindrea Campbell, Zymergen

Q&A: Ain­drea Camp­bell goes small, step­ping away from Ap­ple to head man­u­fac­tur­ing at Zymer­gen — where am­bi­tions are big

Over the past 22 years, Aindrea Campbell has worked with just two corporate giants, Ford Motor Company and Apple, with generations of experience between them. But in her new role as Zymergen’s chief manufacturing officer, Campbell comes to a company with years — eight — of history, not decades.

This month, Campbell joined synthetic biology player Zymergen to lead manufacturing for the company’s “biofacturing” process, which ferments genetically engineered molecules to create products that can be used in a range of potential applications, including electronics, consumer health and agriculture, just to name a few. The process, Zymergen says, obviates the need for toxic chemicals and huge infrastructure demands in traditional manufacturing, potentially cutting costs by 90% in half the time.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Brent Saunders (Richard Drew, AP Images)

OcuWho? Star deal­mak­er turned aes­thet­ics czar Brent Saun­ders flips back in­to biotech. But who’s he team­ing up with now?

Brent Saunders went on a tear of headline-blazing deals building Allergan, merging and rearranging a variety of big companies into one before an M&A pact with Pfizer blew up and sent him on a bout of biotech drug deals. That didn’t work so well, so under pressure, he got his buyout at AbbVie — which needed a big franchise like Botox. And it was no big surprise to see him riding the SPAC wave into a recent $1 billion-plus deal that left him in the executive chairman’s seat at an aesthetics outfit — now redubbed The Beauty Health Company — holding a big chunk of the equity.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.